Details for New Drug Application (NDA): 209611
✉ Email this page to a colleague
NDA 209611 describes LINACLOTIDE, which is a drug marketed by Aurobindo Pharma and Mylan and is included in two NDAs. Additional details are available on the LINACLOTIDE profile page.
The generic ingredient in LINACLOTIDE is linaclotide. There are ten drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the linaclotide profile page.
The generic ingredient in LINACLOTIDE is linaclotide. There are ten drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the linaclotide profile page.
Summary for 209611
| Tradename: | LINACLOTIDE |
| Applicant: | Aurobindo Pharma |
| Ingredient: | linaclotide |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 145MCG | ||||
| Approval Date: | Feb 7, 2023 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 290MCG | ||||
| Approval Date: | Feb 7, 2023 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
